![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
05 juin 2014 08h01 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals Reports First Quarter 2014 Financial Results
06 mai 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 6, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2014.
For the first quarter...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform
02 mai 2014 08h47 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 2, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
30 avr. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals Announces Date of First Quarter 2014 Financial Results Conference Call and Webcast
15 avr. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 34th Annual Health Care Conference
24 févr. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results
10 févr. 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2013.
For the...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals to Webcast Presentation at the 2014 Leerink Global Healthcare Conference
05 févr. 2014 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
21 janv. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
![Momenta Pharmaceuticals logo](/news-release/logo/330730/0/330730.jpg?lastModified=12%2F09%2F2016%2022%3A36%3A50&size=2)
Momenta Pharmaceuticals Appoints Michael Franken, M.D. as President, Biosimilars Business
12 déc. 2013 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) announced today that it has named Michael Franken, M.D. as President, Biosimilars Business. Dr. Franken...